1. Home
  2. QH vs PHGE Comparison

QH vs PHGE Comparison

Compare QH & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

N/A

Current Price

$3.42

Market Cap

14.8M

ML Signal

N/A

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

N/A

Current Price

$0.68

Market Cap

15.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QH
PHGE
Founded
2012
2015
Country
China
United States
Employees
N/A
57
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
15.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
QH
PHGE
Price
$3.42
$0.68
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
155.8K
9.3M
Earning Date
04-02-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.25
52 Week High
$10.85
$8.50

Technical Indicators

Market Signals
Indicator
QH
PHGE
Relative Strength Index (RSI) 58.61 38.64
Support Level $0.46 $0.41
Resistance Level $7.76 $1.89
Average True Range (ATR) 0.71 0.24
MACD 0.18 0.03
Stochastic Oscillator 31.84 19.38

Price Performance

Historical Comparison
QH
PHGE

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: